GlobeNewsWire
17 Jun 2026, 07:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Resolution Therapeutics is awaiting interim data from its Phase 1/2 EMERALD clinical study for end-stage liver disease later this year. — Clinical trial data for a lead asset in a high-unmet-need population (end-stage liver disease) is the most significant catalyst for a biopharma company's valuation.
+0.80The company has entered Material Transfer Agreements with LNP providers to develop an in vivo delivery platform for Regenerative Macrophage Therapy. — Transitioning from autologous to in vivo delivery significantly expands the addressable patient market and scalability, though it is currently in early-stage assessment.
+0.40Resolution expects preliminary results from its systematic assessments of LNP formulations by the end of the year. — Provides a concrete near-term milestone for the new platform's viability, though it is pre-clinical.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
12h ago
